Allarity Therapeutics (NASDAQ:ALLR) Given New $9.25 Price Target at Ascendiant Capital Markets

Allarity Therapeutics (NASDAQ:ALLR) had its target price raised by Ascendiant Capital Markets from $9.00 to $9.25 in a research report sent to investors on Friday morning,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Separately, Wall Street Zen upgraded Allarity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $9.25.

Allarity Therapeutics Stock Performance

Shares of ALLR opened at $1.58 on Friday. Allarity Therapeutics has a 1 year low of $0.61 and a 1 year high of $2.35. The stock’s 50-day moving average price is $1.31 and its two-hundred day moving average price is $1.08.

Allarity Therapeutics (NASDAQ:ALLR) last issued its earnings results on Friday, August 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.06. On average, research analysts forecast that Allarity Therapeutics will post -78.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Allarity Therapeutics

Institutional investors have recently modified their holdings of the business. Jane Street Group LLC acquired a new stake in Allarity Therapeutics in the 2nd quarter valued at approximately $27,000. XTX Topco Ltd acquired a new stake in Allarity Therapeutics in the 2nd quarter valued at approximately $51,000. Finally, Geode Capital Management LLC raised its position in Allarity Therapeutics by 49.3% in the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after buying an additional 16,729 shares during the last quarter. Institutional investors own 11.53% of the company’s stock.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.